-
1
-
-
0035822038
-
The hemophilias--from royal genes to gene therapy
-
Mannucci PM, Tuddenham EG. The hemophilias--from royal genes to gene therapy. N Engl J Med 2001; 344: 1773-9,
-
(2001)
N Engl J Med
, vol.344
, pp. 1773-1779
-
-
Mannucci, P.M.1
Tuddenham, E.G.2
-
2
-
-
0020500234
-
Redetermination of the rate-limiting step in the activation of factor IX by factor XIa and by factor VIIa/tissue factor. Explanation for different electrophoretic radioactivity profiles obtained on activation of 3H-and 125I-labeled factor IX
-
Bajaj SP, Rapaport SI, Russell WA. Redetermination of the rate-limiting step in the activation of factor IX by factor XIa and by factor VIIa/tissue factor. Explanation for different electrophoretic radioactivity profiles obtained on activation of 3H-and 125I-labeled factor IX. Biochemistry 1983; 22: 4047-53.
-
(1983)
Biochemistry
, vol.22
, pp. 4047-4053
-
-
Bajaj, S.P.1
Rapaport, S.I.2
Russell, W.A.3
-
3
-
-
0019831499
-
The role of phospholipid and factor VIIIa in the activation of bovine factor X
-
van Dieijen G, Tans G, Rosing J et al. The role of phospholipid and factor VIIIa in the activation of bovine factor X. J Biol Chem 1981; 256: 3433-42.
-
(1981)
J Biol Chem
, vol.256
, pp. 3433-3442
-
-
van Dieijen, G.1
Tans, G.2
Rosing, J.3
-
5
-
-
0034670013
-
Activation of factor IX zymogen results in exposure of a binding site for low-density lipoprotein receptor-related protein
-
Neels J, van den Berg B, Mertens K et al. Activation of factor IX zymogen results in exposure of a binding site for low-density lipoprotein receptor-related protein. Blood 2000; 96: 3459-s65.
-
(2000)
Blood
, vol.96
-
-
Neels, J.1
van den Berg, B.2
Mertens, K.3
-
6
-
-
0029887334
-
The treatment of haemophilia, including prophylaxis, constant infusion and DDAVP
-
Berntorp E. The treatment of haemophilia, including prophylaxis, constant infusion and DDAVP. Baillieres Clin Haematol 1996; 9: 259-71.
-
(1996)
Baillieres Clin Haematol
, vol.9
, pp. 259-271
-
-
Berntorp, E.1
-
7
-
-
0030841284
-
High cost, low volume care: The ease of haemophilia
-
Lee C, Sabin C, Miners A. High cost, low volume care: the ease of haemophilia. BMJ 1997; 315: 962-3.
-
(1997)
BMJ
, vol.315
, pp. 962-963
-
-
Lee, C.1
Sabin, C.2
Miners, A.3
-
8
-
-
0036210038
-
Clinical outcomes and resource utilization associated with haemophilia care in Europe
-
Schramm W, Royal S, Kroner B et al. Clinical outcomes and resource utilization associated with haemophilia care in Europe. Haemophilia 2002; 8: 33-43.
-
(2002)
Haemophilia
, vol.8
, pp. 33-43
-
-
Schramm, W.1
Royal, S.2
Kroner, B.3
-
9
-
-
0027411861
-
Factor IX concentrates for clinical use
-
Thompson AR. Factor IX concentrates for clinical use. Semin Thromb Hemost 1993; 19: 25-36.
-
(1993)
Semin Thromb Hemost
, vol.19
, pp. 25-36
-
-
Thompson, A.R.1
-
10
-
-
0036484156
-
Pharmacokinetic analysis of plasma-derived and recombinant F IX concentrates in previously treated patients with moderate or severe hemophilia B
-
Ewenstein BM, Joist JH, Shapiro AD et al. Pharmacokinetic analysis of plasma-derived and recombinant F IX concentrates in previously treated patients with moderate or severe hemophilia B. Transfusion 2002; 42: 190-7.
-
(2002)
Transfusion
, vol.42
, pp. 190-197
-
-
Ewenstein, B.M.1
Joist, J.H.2
Shapiro, A.D.3
-
11
-
-
0036660414
-
Circulating and binding characteristics of wild-type factor IX and certain Gla domain mutants in vivo
-
Gui T, Lin HF, Jin DY et al. Circulating and binding characteristics of wild-type factor IX and certain Gla domain mutants in vivo. Blood 2002; 100: 153-8.
-
(2002)
Blood
, vol.100
, pp. 153-158
-
-
Gui, T.1
Lin, H.F.2
Jin, D.Y.3
-
12
-
-
0026660188
-
The binding of human factor IX to endothelial cells is mediated by residues 3-11
-
Cheung WF, Hamaguchi N, Smith KJ et al. The binding of human factor IX to endothelial cells is mediated by residues 3-11. J Biol Chem 1992; 267: 20529-31.
-
(1992)
J Biol Chem
, vol.267
, pp. 20529-20531
-
-
Cheung, W.F.1
Hamaguchi, N.2
Smith, K.J.3
-
13
-
-
15244354145
-
Factor IX variants improve gene therapy efficacy for hemophilia B
-
Schuettrumpf J, Herzog RW, Schlachterman A et al. Factor IX variants improve gene therapy efficacy for hemophilia B. Blood 2005; 105: 2316-23.
-
(2005)
Blood
, vol.105
, pp. 2316-2323
-
-
Schuettrumpf, J.1
Herzog, R.W.2
Schlachterman, A.3
-
14
-
-
0027532543
-
Domain structure and domain-domain interactions in human coagulation factor IX
-
Vysotchin A, Medved LV, Ingham KC. Domain structure and domain-domain interactions in human coagulation factor IX. J Biol Chem 1993; 268: 8436-46.
-
(1993)
J Biol Chem
, vol.268
, pp. 8436-8446
-
-
Vysotchin, A.1
Medved, L.V.2
Ingham, K.C.3
-
15
-
-
17644445635
-
Biochemical characterization of recombinant factor IX
-
Bond M, Jankowski M, Patel H et al. Biochemical characterization of recombinant factor IX. Semin Hematol 1998; 35: 11-7.
-
(1998)
Semin Hematol
, vol.35
, pp. 11-17
-
-
Bond, M.1
Jankowski, M.2
Patel, H.3
-
17
-
-
0033587143
-
Persistent delivery of factor IX in mice: Gene therapy for hemophilia using implantable microcapsules
-
Hortelano G, Xu N, Vandenberg A et al. Persistent delivery of factor IX in mice: gene therapy for hemophilia using implantable microcapsules. Hum Gene Ther 1999; 10: 1281-8.
-
(1999)
Hum Gene Ther
, vol.10
, pp. 1281-1288
-
-
Hortelano, G.1
Xu, N.2
Vandenberg, A.3
-
18
-
-
0029685880
-
Immunoaffinity chromatography
-
Jack GW, Beer DJ. Immunoaffinity chromatography. Methods Mol Biol 1996; 59: 187-96.
-
(1996)
Methods Mol Biol
, vol.59
, pp. 187-196
-
-
Jack, G.W.1
Beer, D.J.2
-
19
-
-
4143091398
-
Effects of genetic fusion of factor IX to albumin on in vivo clearance in mice and rabbits
-
Sheffield WP, Mamdani A, Hortelano G et al. Effects of genetic fusion of factor IX to albumin on in vivo clearance in mice and rabbits. Br J Haematol 2004; 126: 565-73.
-
(2004)
Br J Haematol
, vol.126
, pp. 565-573
-
-
Sheffield, W.P.1
Mamdani, A.2
Hortelano, G.3
-
20
-
-
0016231936
-
Comparative evaluation of a partial thromboplastin reagent containing a non-settling, particulate activator
-
Babson AL, Babson SR. Comparative evaluation of a partial thromboplastin reagent containing a non-settling, particulate activator. Am J Clin Pathol 1974; 62: 856-60.
-
(1974)
Am J Clin Pathol
, vol.62
, pp. 856-860
-
-
Babson, A.L.1
Babson, S.R.2
-
21
-
-
0030758328
-
A factor IX-deficient mouse model for hemophilia B gene therapy
-
Wang L, Zoppe M, Hackeng TM et al. A factor IX-deficient mouse model for hemophilia B gene therapy. Proc Natl Acad Sci U S A 1997; 94: 11563-6.
-
(1997)
Proc Natl Acad Sci U S A
, vol.94
, pp. 11563-11566
-
-
Wang, L.1
Zoppe, M.2
Hackeng, T.M.3
-
22
-
-
0035082874
-
Sustained and therapeutic delivery of factor IX in nude haemophilia B mice by encapsulated C2C12 myoblasts: Concurrent tumourigenesis
-
Hortelano G, Wang L, Xu N et al. Sustained and therapeutic delivery of factor IX in nude haemophilia B mice by encapsulated C2C12 myoblasts: concurrent tumourigenesis. Haemophilia 2001; 7: 207-14.
-
(2001)
Haemophilia
, vol.7
, pp. 207-214
-
-
Hortelano, G.1
Wang, L.2
Xu, N.3
-
23
-
-
0034663089
-
Mutation of any site of N-linked glycosylation accelerates the in vivo clearance of recombinant rabbit antithrombin
-
Ni H, Blajchman MA, Ananthanarayanan VS et al. Mutation of any site of N-linked glycosylation accelerates the in vivo clearance of recombinant rabbit antithrombin. Thromb Res 2000; 99: 407-15.
-
(2000)
Thromb Res
, vol.99
, pp. 407-415
-
-
Ni, H.1
Blajchman, M.A.2
Ananthanarayanan, V.S.3
-
24
-
-
1242294497
-
A covalently linked recombinant albumin dimer is more rapidly cleared in vivo than are wild-type and mutant C34A albumin
-
McCurdy TR, Gataiance S, Eltringham-Smith LJ et al. A covalently linked recombinant albumin dimer is more rapidly cleared in vivo than are wild-type and mutant C34A albumin. J Lab Clin. Med 2004; 143: 115-24.
-
(2004)
J Lab Clin. Med
, vol.143
, pp. 115-124
-
-
McCurdy, T.R.1
Gataiance, S.2
Eltringham-Smith, L.J.3
-
25
-
-
0028877754
-
An evaluation of numerical integration algorithms for the estimation of the area under the curve (AUC) in pharmacokinetic studies
-
Yu Z, Tse FL. An evaluation of numerical integration algorithms for the estimation of the area under the curve (AUC) in pharmacokinetic studies. Biopharm Drug Dispos 1995; 16: 37-58.
-
(1995)
Biopharm Drug Dispos
, vol.16
, pp. 37-58
-
-
Yu, Z.1
Tse, F.L.2
-
26
-
-
0024594530
-
Antithrombotic and bleeding effects of glycosaminoglycans with different degrees of sulphation
-
Van Ryn-McKenna J, Ofosu FA, Hirsh J et al. Antithrombotic and bleeding effects of glycosaminoglycans with different degrees of sulphation. Br J Haematol 1989; 71: 265-9.
-
(1989)
Br J Haematol
, vol.71
, pp. 265-269
-
-
Van Ryn-McKenna, J.1
Ofosu, F.A.2
Hirsh, J.3
-
27
-
-
0030899507
-
Factor IX activation by factor XIa proceeds without release of a free intermediate
-
Wolberg AS, Morris DP, Stafford DW. Factor IX activation by factor XIa proceeds without release of a free intermediate. Biochemistry 1997; 36: 4074-9.
-
(1997)
Biochemistry
, vol.36
, pp. 4074-4079
-
-
Wolberg, A.S.1
Morris, D.P.2
Stafford, D.W.3
-
28
-
-
17644445635
-
Biochemical characterization of recombinant factor IX
-
Bond M, Jankowski M, Patel H et al. Biochemical characterization of recombinant factor IX. Semin Hematol 1998; 35: 11-17.
-
(1998)
Semin Hematol
, vol.35
, pp. 11-17
-
-
Bond, M.1
Jankowski, M.2
Patel, H.3
-
29
-
-
0024321508
-
Alteration of terminal glycosylation sequences on N-linked oligosaccharides of Chinese hamster ovary cells by expression of beta-galactoside alpha 2,6-sialyltransferase
-
Lee EU, Roth J, Paulson JC. Alteration of terminal glycosylation sequences on N-linked oligosaccharides of Chinese hamster ovary cells by expression of beta-galactoside alpha 2,6-sialyltransferase. J Biol Chem 1989; 264: 13848-55.
-
(1989)
J Biol Chem
, vol.264
, pp. 13848-13855
-
-
Lee, E.U.1
Roth, J.2
Paulson, J.C.3
-
30
-
-
0024278423
-
The immobilized leukoagglutinin from the seeds of Maackia amurensis binds with high affinity to complex-type Asn-linked oligosaccharides containing terminal sialic acid-linked alpha-2,3 to penultimate galactose residues
-
Wang WC, Cummings RD. The immobilized leukoagglutinin from the seeds of Maackia amurensis binds with high affinity to complex-type Asn-linked oligosaccharides containing terminal sialic acid-linked alpha-2,3 to penultimate galactose residues. J Biol Chem 1988; 263: 4576-85.
-
(1988)
J Biol Chem
, vol.263
, pp. 4576-4585
-
-
Wang, W.C.1
Cummings, R.D.2
-
31
-
-
0023644482
-
The elderberry (Sambucus nigra L.) bark lectin recognizes the Neu5Ac(alpha 2-6)Gal/GalNAc sequence
-
Shibuya N, Goldstein IJ, Broekaert WF et al. The elderberry (Sambucus nigra L.) bark lectin recognizes the Neu5Ac(alpha 2-6)Gal/GalNAc sequence. J Biol Chem 1987; 262: 1596-601.
-
(1987)
J Biol Chem
, vol.262
, pp. 1596-1601
-
-
Shibuya, N.1
Goldstein, I.J.2
Broekaert, W.F.3
-
32
-
-
29244489676
-
Role of the activation peptide in factor IX activation
-
Chang J-Y, Allen GA, Monroe DM et al. Role of the activation peptide in factor IX activation. Blood 2000; 96: 632a.
-
(2000)
Blood
, vol.96
-
-
Chang, J.-Y.1
Allen, G.A.2
Monroe, D.M.3
-
33
-
-
0028873221
-
Evaluation of recombinant human factor IX: Pharmacokinetic studies in the rat and the dog
-
Keith JC, Jr., Ferranti TJ, Misra B et al. Evaluation of recombinant human factor IX: pharmacokinetic studies in the rat and the dog. Thromb Haemost 1995; 73: 101-5.
-
(1995)
Thromb Haemost
, vol.73
, pp. 101-105
-
-
Keith Jr., J.C.1
Ferranti, T.J.2
Misra, B.3
-
34
-
-
0021287957
-
Regulation of factor IXa in vitro in human and mouse plasma and in vivo in the mouse. Role of the endothelium and the plasma proteinase inhibitors
-
Fuchs HE, Trapp HG, Griffith MJ et al. Regulation of factor IXa in vitro in human and mouse plasma and in vivo in the mouse. Role of the endothelium and the plasma proteinase inhibitors. J Clin Invest 1984; 73: 1696-703.
-
(1984)
J Clin Invest
, vol.73
, pp. 1696-1703
-
-
Fuchs, H.E.1
Trapp, H.G.2
Griffith, M.J.3
-
35
-
-
0034846845
-
A barbourin-albumin fusion protein that is slowly cleared in vivo retains the ability to inhibit platelet aggregation in vitro
-
Marques JA, George JK, Smith IJ et al. A barbourin-albumin fusion protein that is slowly cleared in vivo retains the ability to inhibit platelet aggregation in vitro. Thromb Haemost 2001; 86: 902-8.
-
(2001)
Thromb Haemost
, vol.86
, pp. 902-908
-
-
Marques, J.A.1
George, J.K.2
Smith, I.J.3
-
36
-
-
0030942608
-
Potent antithrombin activity and delayed clearance from the circulation characterize recombinant hirudin genetically fused to albumin
-
Syed S, Schuyler PD, Kulczycky M et al. Potent antithrombin activity and delayed clearance from the circulation characterize recombinant hirudin genetically fused to albumin. Blood 1997; 89: 3243-52.
-
(1997)
Blood
, vol.89
, pp. 3243-3252
-
-
Syed, S.1
Schuyler, P.D.2
Kulczycky, M.3
-
38
-
-
0036660414
-
Circulating and binding characteristics of wild-type factor IX and certain Gla domain mutants in vivo
-
Gui T, Lin HF, Jin DY et al. Circulating and binding characteristics of wild-type factor IX and certain Gla domain mutants in vivo. Blood 2002; 100: 153-8.
-
(2002)
Blood
, vol.100
, pp. 153-158
-
-
Gui, T.1
Lin, H.F.2
Jin, D.Y.3
-
39
-
-
0032524615
-
Changing residue 338 in human factor IX from arginine to alanine causes an increase in catalytic activity
-
Chang J, Jin J, Lollar P et al. Changing residue 338 in human factor IX from arginine to alanine causes an increase in catalytic activity. J Biol Chem 1998; 273: 12089-94.
-
(1998)
J Biol Chem
, vol.273
, pp. 12089-12094
-
-
Chang, J.1
Jin, J.2
Lollar, P.3
|